BidaskClub Lowers Ironwood Pharmaceuticals (IRWD) to Strong Sell

BidaskClub cut shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from a sell rating to a strong sell rating in a report issued on Monday morning.

Other equities analysts have also issued research reports about the company. Credit Suisse Group began coverage on Ironwood Pharmaceuticals in a research note on Monday, November 27th. They issued a buy rating and a $19.00 price target on the stock. Mizuho lowered Ironwood Pharmaceuticals from a buy rating to a neutral rating and decreased their target price for the stock from $20.00 to $16.00 in a research note on Wednesday, December 6th. Zacks Investment Research lowered Ironwood Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, January 9th. Bank of America lowered Ironwood Pharmaceuticals from a buy rating to an underperform rating and decreased their target price for the stock from $20.00 to $15.00 in a research note on Friday, January 5th. Finally, Morgan Stanley reissued a hold rating on shares of Ironwood Pharmaceuticals in a research note on Monday, December 4th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company. The stock has an average rating of Hold and a consensus target price of $17.56.

Ironwood Pharmaceuticals (NASDAQ IRWD) opened at $13.67 on Monday. Ironwood Pharmaceuticals has a 12 month low of $12.89 and a 12 month high of $19.94. The company has a debt-to-equity ratio of -22.31, a quick ratio of 4.86 and a current ratio of 4.87.

In related news, CEO Peter M. Hecht sold 113,405 shares of the stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $15.12, for a total transaction of $1,714,683.60. Following the transaction, the chief executive officer now owns 4,696,917 shares of the company’s stock, valued at approximately $71,017,385.04. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Mark G. Currie sold 60,000 shares of the stock in a transaction dated Wednesday, January 24th. The stock was sold at an average price of $15.45, for a total value of $927,000.00. Following the transaction, the insider now directly owns 835,000 shares in the company, valued at approximately $12,900,750. The disclosure for this sale can be found here. In the last three months, insiders have sold 174,905 shares of company stock worth $2,666,359. 7.63% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Ironwood Pharmaceuticals by 128.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,010 shares of the biotechnology company’s stock valued at $135,000 after purchasing an additional 5,069 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management acquired a new stake in Ironwood Pharmaceuticals in the 3rd quarter valued at about $170,000. Hemenway Trust Co LLC acquired a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at about $204,000. Ameritas Investment Partners Inc. raised its position in Ironwood Pharmaceuticals by 5.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 648 shares in the last quarter. Finally, Virtu KCG Holdings LLC raised its position in Ironwood Pharmaceuticals by 10.3% in the 2nd quarter. Virtu KCG Holdings LLC now owns 15,740 shares of the biotechnology company’s stock valued at $297,000 after purchasing an additional 1,470 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: This news story was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.com-unik.info/2018/02/09/bidaskclub-lowers-ironwood-pharmaceuticals-irwd-to-strong-sell-2.html.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit